Organoid vs In Vivo Mouse Model: Which is Better Research Tool to Understand the Biologic Mechanisms of Intestinal Epithelium?

Shinya Sugimoto, MD, PhD1,2 and Toshiro Sato, MD, PhD1,2

1Department of Organoid Medicine, Keio University School of Medicine, Tokyo, Japan; and 2Department of Gastroenterology, Keio University School of Medicine, Tokyo, Japan

The mammalian intestinal epithelium consists of the glandular histologic unit, crypts. Crypts have a remarkable self-renewing capacity, and the entire unit is constantly regenerated within several days. The self-renewing capacity is instrumental for homeostasis and critical after intestinal injury, when new crypts must be formed from a landscape of denuded mucosa. Mouse models have provided an understanding of how crypts regenerate and which factors regulate the self-renewal of crypts. In the 1970s, Leblond, Cheng, and Bjerknes revealed the self-renewing dynamics of mouse intestinal crypts and proposed intestinal stem cells (ISCs) responsible for crypt self-renewal.1,2 However, ISCs were not formally identified until the emergence of a lineage tracing system using mouse genetic models, when Barker and Clevers demonstrated the long-term self-renewing potential and multidifferentiation capacity of Lgr5+ ISCs.3 The Lgr5 expression indicated the critical role of Wnt signaling in the maintenance of ISCs. Moreover, this finding underscored that microenvironmental factors, referred to as niche factors, could be used to support ISCs. Using a combination of niche factors including EGF (growth factor), Noggin (Bmp inhibitor), and R-spondin (Wnt signaling activator), Sato and Clevers developed an organoid culture system for mouse small intestinal epithelium.4

Ever since the establishment of the organoid culture system, mouse genetic models and organoids have been 2 major tools to study ISCs and crypt development. Here, we discuss the advantages of the organoid culture system over mouse genetic models (Table 1).

The first, and most obvious, advantage of organoids is the applicability to the human intestinal epithelium. Although mouse intestinal epithelium shares major biologic and histologic traits with humans, recent studies highlighted several differences. Human and mouse organoids differ in their dependence on niche factors, suggesting fundamental differences in the molecular mechanisms of self-renewal in mouse versus human ISCs.5 There are unique epithelial cell types found in humans but not in mouse, such as motilin+ enteroendocrine cells and BEST4+/OTOP2+ cells,6,7 which may suggest different constraints during crypt development and regeneration. Organoids regenerated these cell types and might be able to reveal their as-yet-unknown function. Moreover, the effects of environmental signals, such as certain human microbes or the human diet, can be species-specific; to understand their roles in crypt development it is essential to use species-matched host cells, something that is readily achieved with organoids.

The second advantage is the throughput of the experimental platform. Both mouse genetic models and organoids provide causal evidence of pharmaceutical and genetic targeting. However, the throughput of organoid-based assays outweighs that of mouse models. Organoids can be plated in large multiplex arrays for drug screening or CRISPR-Cas9 editing. Such an increase in throughput in mouse models would raise miscellaneous issues, such as animal ethics, labor-intensive procedures, and mouse housing costs. Imaging-based screening of organoids has led to the discovery of key molecules regulating crypt development.8 The advance of organoid-based imaging analysis by overcoming phototoxicity will drive further understanding of the crypt self-renewing mechanism. In addition, the potential differences between homeostatic state and regeneration phase should be taken into consideration because it is generally believed that early organoid growth primarily models regeneration.

Third, organoids provide a tractable technical platform to understand spatiotemporal regulation of crypt morphogenesis. Neonatal intestines start to form a crypt-villus axis along with the initiation of Paneth cell differentiation. After the initial maturation, adult mouse intestines undergo homeostatic regeneration, in which not only are individual cells constantly replaced, but also the total number of crypt units are maintained through a fluid combination of whole-crypt fission or fusion events. Although the dynamics of crypt development could, in principle, be captured by a high-end intravital imaging system, the detailed mechanisms remain elusive because of a lack of a manipulatable experimental platform. Organoid studies will help to bridge this gap. Budding events in organoids are broadly similar to crypt fission, an important mechanism through which crypts regenerate in vivo. Because budding occurs frequently and rapidly in organoids, this process can be interrogated using traditional microscopy. In addition to specific changes in the local density of stem and Paneth cells,9 factors that drive budding include mechanical force.10 Thus, organoid-based studies
enable high spatiotemporal resolution and perturbation of crypt-villus development.

Although intestinal organoids derived from adult human tissues emulate the diversity of in vivo intestinal epithelial cell types, it is true that they lack vascularization, neural innervation, fluid flow, interactions with other cells (eg, endothelial, mesenchymal, and immune cells), and intestinal luminal contents. To understand these complicated interactions between epithelium and nonepithelial cells, mouse models are currently the best experimental platform. However, in this specific regard, the gap between mouse models and organoids may be quickly closing. There has been some success in the coculture of organoids with other cell types (eg, endothelial cells). However, it remains undetermined to what extent these coculture systems recapitulate the heterocellular interactions in vivo, and further optimization is required to tackle this challenge through the development of advanced culture platforms. As an alternative to the coculture system, organoid transplantation could provide an opportunity for the assessment of heterocellular interactions. We and others have established an organoid transplantation system to investigate epithelium-stromal interaction in vivo. On the heterotopic interaction between small intestinal epithelium and colonic stroma, the engineered colon formed crypt-villus structures and lacteals, unique histologic features found in the small intestine, and rescued short bowel syndrome model in rats. This result suggested that the heterocellular interaction instructs intrinsic tissue morphogenesis, findings that could be translated to regenerative medicine. The transplantation system can also be used to investigate the human intestinal epithelium in a tissue context. Interestingly, orthotopically transplanted human colonic organoids formed crypts that more closely resembled human colonic crypts than the surrounding mouse crypts. Furthermore, CRISPR-Cas9-mediated genome editing enabled genetic studies of human intestinal epithelium in vivo, such as genetic lineage tracing of human LGR5 and precise disease modeling of human colon tumorigenesis. Therefore, the transplantation system offers a complementary approach to understand stem cell function and crypt morphogenesis of organoids in a tissue context.

In conclusion, organoids are the best research tool to study the biology of human intestinal epithelium and provide a complementary and alternative approach to the understanding of mouse intestinal physiology.

Table 1. Characteristics of Organoid vs Mouse Models

| Characteristics                             | Organoids                                      | In vivo mouse models |
|---------------------------------------------|------------------------------------------------|---------------------|
| Species                                     | Human, mouse, rat, pig, and so forth           | Mouse               |
| Derivation                                  | Healthy/diseased tissue-derived or pluripotent-stem cell-derived | Wild-type or genetic engineering mouse model |
| In vitro                                    | +++                                            | ++\(^a\)            |
| In vivo                                     | - ~ +\(^b\)                                    | +++                 |
| Cost                                        | + ~ ++                                         | ++                  |
| Technical difficulty                        | In vitro: ++                                   | In vivo: +++         |
| Throughput                                  | +++                                            | - ~ +               |
| Genetic manipulation                        | <1 mo                                          | >3–6 mo             |
| Human genetic relevance                     | +                                              | -                   |
| Relevant microenvironment                   | - ~ +\(^c\)                                    | +++                 |
| Regulation                                  | Ethical committee approval                     | Animal committee approval |

\(^a\) Mouse organoids can also be established from mouse models.
\(^b\) Transplantation enables in vivo assessment.
\(^c\) Coculture system or transplantation recapitulate the microenvironment.

References

1. Cheng H, Leblond CP. Origin, differentiation and renewal of the four main epithelial cell types in the mouse small intestine. V. Unitarian theory of the origin of the four epithelial cell types. Am J Anat 1974;141:537–561.
2. Bjerknes M, Cheng H. Clonal analysis of mouse intestinal epithelial progenitors. Gastroenterology 1999;116:7–14.
3. Barker N, van Es JH, Kuipers J, Kujala P, van den Born M, Cozijnsen M, Haegbarth A, Korving J, Begthel H, Peters P, Clevers H. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 2007;449:1003–1007.
4. Sato T, Vries RG, Snippert HJ, van de Wetering M, Barker N, Stange DE, van Es JH, Abo A, Kujala P, Peters PJ, Clevers H. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 2009;459:262–265.
human colon, adenoma, adenocarcinoma, and Barrett’s epithelium. Gastroenterology 2011; 141:1762–1772.
6. Fujii M, Matano M, Toshimitsu K, Takano A, Mikami Y, Nishikoti, Sugimoto S, Sato T. Human intestinal organoids maintain self-renewal capacity and cellular diversity in niche-inspired culture condition. Cell Stem Cell 2018; 23:787–793.
7. Parikh K, Antanaviciute A, Fawker-Corbett D, Marta J, Aulicino A, Lagerholm C, Davis S, Kinchen J, Chen HH, Alham NK, Ashley N, Johnson E, Hublitz P, Bao L, Lukomska J, Andev RS, Björklund E, Kessler BM, Fischer R, Goldin R, Koohy H, Simmons A. Colonic epithelial cell diversity in health and inflammatory bowel disease. Nature 2019;567:49–55.
8. Lukonin I, Serra D, Challet Meylan L, Volkmann K, Baaten J, Zhao R, Meeusen S, Colman K, Maurer F, Stadler MB, Jenkins J, Liberall P. Phenotypic landscape of intestinal organoid regeneration. Nature 2020;586:275–280.
9. Langlands AJ, Almet AA, Appleton PL, Newton IP, Osborne JM, Náthke IS. Paneth cell-rich regions separated by a cluster of Lgr5+ cells initiate crypt fission in the intestinal stem cell niche. PLoS Biol 2016;14: e1002491.
10. Tallapragada NP, Cambra HM, Wald T, Jaibert SK, Abraham DM, Klein OD, Klein AM. Inflation-collapse dynamics drive patterning and morphogenesis in intestinal organoids. Cell Stem Cell 2021.
11. Palikuqi B, Nguyen D-HT, Li G, Schreiner R, Pellegata AF, Liu Y, Redmond D, Geng F, Lin Y, Gómez-Saliner JM, Yokoyama M, Zumbo P, Zhang T, Kunar B, Witherspoon M, Han T, Tedeshi AM, Scottoni F, Lipkin SM, Dow L, Elemento O, Xiang JZ, Shido K, Spence JR, Zhou QJ, Schwartz RE, De Coppi P, Rabban SY, Rafii S. Adaptable haemodynamic endothelial cells for organogenesis and tumorgenesis. Nature 2020; 585:426–432.
12. Sugimoto S, Ohta Y, Fujii M, Mantano M, Shimokawa M, Nanki K, Date S, Nishikori S, Nakazato Y, Nakamura T, Kanai T, Sato T. Reconstruction of the human colon epithelium in vivo. Cell Stem Cell 2018; 22:171–176.
13. Sugimoto S, Kobayashi E, Fujii M, Ohta Y, Arai K, Matano M, Ishikawa K, Miyamoto K, Toshimitsu K, Takahashi S, Nanki K, Hakamata Y, Kanai T, Sato T. An organoid-based organ-repurposing approach to treat short bowel syndrome. Nature 2021;592:99–104.
14. Kawasaki K, Fujii M, Sugimoto S, Ishikawa K, Matano M, Ohta, Toshimitsu K, Takahashi S, Hosoe N, Sekine S, Kanai T, Sato T. Chromosome engineering of human colon-derived organoids to develop a model of traditional serrated adenoma. Gastroenterology 2020; 158:638–651.

Correspondence
Address correspondence to: Toshiro Sato, MD, PhD, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan. e-mail: t.sato@keio.jp.

Conflicts of interest
Toshiro Sato is an inventor on several patents related to organoid culture. The remaining author discloses no conflicts.

Funding
This work was in part supported by Japan Agency for Medical Research and Development (AMED) (grant numbers JP21ek0109523, JP21bm0704069, and JP18bm0304001), AMED-CREST (grant number JP18gm1210001), JSPS KAKENHI (grant numbers JP21K19540, JP20H03746 and JP17H06176), The Mochida Memorial Foundation for Medical and Pharmaceutical Research, Takeda Science Foundation, Keio University Medical Science Funds, and Keio University Academic Development Funds.